↓ Skip to main content

Dove Medical Press

Article Metrics

Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene

Overview of attention for article published in Therapeutics and Clinical Risk Management, April 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
61 Mendeley
Title
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene
Published in
Therapeutics and Clinical Risk Management, April 2016
DOI 10.2147/tcrm.s63833
Pubmed ID
Authors

Risa Kagan, Steven R. Goldstein, James H. Pickar, Barry S. Komm

Abstract

Menopausal symptoms (eg, hot flushes and vaginal symptoms) are common, often bothersome, and can adversely impact women's sexual functioning, relationships, and quality of life. Estrogen-progestin therapy was previously considered the standard care for hormone therapy (HT) for managing these symptoms in nonhysterectomized women, but has a number of safety and tolerability concerns (eg, breast cancer, stroke, pulmonary embolism, breast pain/tenderness, and vaginal bleeding) and its use has declined dramatically in the past decade since the release of the Women's Health Initiative trial results. Conjugated estrogens paired with bazedoxifene (CE/BZA) represent a newer progestin-free alternative to traditional HT for nonhysterectomized women. CE/BZA has demonstrated efficacy in reducing the frequency and severity of vasomotor symptoms and preventing loss of bone mineral density in postmenopausal women. CE/BZA provides an acceptable level of protection against endometrial hyperplasia and does not increase mammographic breast density. Compared with traditional estrogen-progestin therapy, it is associated with lower rates of breast pain/tenderness and vaginal bleeding. Patient-reported outcomes indicate that CE/BZA improves menopause-specific quality of life, sleep, some measures of sexual function (especially ease of lubrication), and treatment satisfaction. This review looks at the rationale for selection and combination of CE with BZA at the dose ratio in the approved product and provides a detailed look at the efficacy, safety, tolerability, and patient-reported outcomes from the five Phase III trials. Patient considerations in the choice between CE/BZA and traditional HT (eg, tolerability, individual symptoms, and preferences for route of administration) are also considered.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 23%
Student > Bachelor 13 21%
Researcher 7 11%
Student > Ph. D. Student 5 8%
Student > Doctoral Student 4 7%
Other 10 16%
Unknown 8 13%
Readers by discipline Count As %
Medicine and Dentistry 27 44%
Nursing and Health Professions 7 11%
Psychology 6 10%
Engineering 2 3%
Agricultural and Biological Sciences 2 3%
Other 4 7%
Unknown 13 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2016.
All research outputs
#7,206,486
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#478
of 922 outputs
Outputs of similar age
#124,074
of 266,599 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#21
of 54 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,599 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.